Steris PLC (STE) Given Average Recommendation of “Buy” by Brokerages

Shares of Steris PLC (NYSE:STE) have received a consensus recommendation of “Buy” from the six analysts that are presently covering the company, reports. Three research analysts have rated the stock with a hold rating and three have issued a buy rating on the company. The average 12 month price objective among analysts that have updated their coverage on the stock in the last year is $72.33.

STE has been the subject of a number of analyst reports. KeyCorp restated an “overweight” rating and issued a $101.00 price objective (up from $91.00) on shares of Steris in a research report on Thursday, November 2nd. Zacks Investment Research lowered shares of Steris from a “buy” rating to a “sell” rating in a research report on Monday, November 6th. TD Securities raised their price objective on shares of Steris from C$14.00 to C$16.00 and gave the company a “buy” rating in a research report on Thursday, November 9th. Finally, Raymond James Financial raised their price objective on shares of Steris from $95.00 to $100.00 and gave the company an “outperform” rating in a research report on Monday, October 16th.

Steris (NYSE STE) opened at $91.96 on Monday. The company has a debt-to-equity ratio of 0.48, a current ratio of 2.80 and a quick ratio of 2.18. Steris has a 1 year low of $65.26 and a 1 year high of $93.71. The company has a market cap of $7,821.38, a P/E ratio of 54.74 and a beta of 1.27.

Steris (NYSE:STE) last released its quarterly earnings data on Wednesday, November 1st. The medical equipment provider reported $0.94 EPS for the quarter, missing analysts’ consensus estimates of $0.95 by ($0.01). Steris had a net margin of 5.59% and a return on equity of 11.49%. The firm had revenue of $634.20 million during the quarter, compared to the consensus estimate of $629.02 million. During the same quarter last year, the business posted $0.89 earnings per share. Steris’s revenue was down 1.9% compared to the same quarter last year. analysts predict that Steris will post 4.06 EPS for the current fiscal year.

In related news, VP John Adam Zangerle sold 3,650 shares of the firm’s stock in a transaction that occurred on Tuesday, November 14th. The shares were sold at an average price of $88.00, for a total value of $321,200.00. The sale was disclosed in a filing with the SEC, which is available through this link. Company insiders own 2.55% of the company’s stock.

Institutional investors and hedge funds have recently made changes to their positions in the stock. Zions Bancorporation purchased a new stake in Steris in the third quarter valued at approximately $178,000. Citigroup Inc. purchased a new stake in Steris in the second quarter valued at approximately $206,000. Oakbrook Investments LLC purchased a new stake in Steris in the fourth quarter valued at approximately $271,000. GSA Capital Partners LLP purchased a new position in shares of Steris during the third quarter worth approximately $284,000. Finally, Atria Investments LLC purchased a new position in shares of Steris during the fourth quarter worth approximately $292,000. 89.44% of the stock is currently owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY WARNING: This article was reported by American Banking News and is the property of of American Banking News. If you are viewing this article on another publication, it was stolen and republished in violation of US and international copyright legislation. The legal version of this article can be viewed at

Steris Company Profile

STERIS plc provides infection prevention and other procedural products and services. The Company operates through four segments: Healthcare Products, which offers infection prevention and procedural solutions for healthcare providers, including capital equipment and related maintenance, and installation services, as well as consumables; Healthcare Specialty Services, which provides a range of specialty services for healthcare providers, including hospital sterilization services, instrument and scope repairs, and linen management; Life Sciences, which offers capital equipment and consumable products, and equipment maintenance and specialty services for pharmaceutical manufacturers and research facilities, and Applied Sterilization Technologies, which offers contract sterilization and laboratory services for medical device and pharmaceutical customers and others.

Receive News & Ratings for Steris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Steris and related companies with's FREE daily email newsletter.

Leave a Reply